Abstract:Objective To study if the protective effect of dexmedetomidine on the pyohemia-associated delirium is through the cholinergic anti-inflammatory pathway.Methods Sixty male adult C57 mice were randomly divided into five groups (n=12 each): saline group (group C),dexmedetomidine (DEX) alone group (group DEX),endotoxemia (LPS) group (group LPS),dexmedetomidine protection group (group LPS+DEX) and alpha-bungarotoxin (α-BGT) group (group α-BGT).Each group were assigned to two subunits (n=6 each),mice in subunit one were sacrificed after examining the open field test,mice in subunit two were sacrificed after testing the novel object recognition.The level of inflammatory factors were measured by enzyme-linked immune sorbent assay (ELISA).The ultrastructure changes of the hippocampus in mice were observed by transmission electron microscopy.Results Compared with group C,there are no significant differences in group DEX.Dexmedetomidine significantly attenuated the delirious syndrome after LPS induced endotoxemia,however,the effect of dexmedetomidine disappeared in group α-BGT,and the syndrome of cognitive dysfunction in LPS group were more severe than that in group α-BGT.(1) The open field test show that there are no significant differences each group with that before model establishment;after the models were established 24 h,compared with group C,group LPS show that the abilities of cognition to new environment、learning and memory were decreasing,the tension is increasing.preemptive administration of dexmedetomidine significantly attenuated the delirious syndrome after LPS induced endotoxemia;however,preemptive administration of dexmedetomidine failed to control the delirious syndrome in group α-BGT.(2) The novel object recognition testshow that compared to group C,the ability of exploring the novel object is decreasing;preemptive administration of dexmedetomidine significantly improve the exploration ability,however,preemptive administration of dexmedetomidine failed to control the delirious syndrome in group α-BGT.(3) The results of ELISA show that: Compared with group C,the concentrations of tumor necrosis factor-α (TNF-α) and interleukin (IL)-1β in serum and Hippocampus were all increased in LPS groups[Serum (ng/L) TNF-α: 794.80±93.99 vs.23.60±3.03,IL-1β: 148.49±24.80 vs.64.55±5.13,Hippocampus (pg/mg·prot) TNF-α: 176.14±11.25 vs.6.71±0.49,IL-1β: 50.61±5.86 vs.16.73±1.15,P=0.000],compared with group LPS,the concentrations were all significantly decreased in group LPS+DEX[Serum (ng/L) TNF-α: 184.44±26.58 vs.794.80±93.99,IL-1β: 77.43±10.75 vs.148.49±24.80,Hippocampus (pg/mg·prot) TNF-α: 64.83±13.09 vs.176.14±11.25,IL-1β: 17.97±2.26 vs.50.61±5.86,P=0.000].However,α-BGT can reverse the protective effect[Serum (ng/L): TNF-α: 812.31±86.25 vs.184.44±26.58,IL-1β: 156.42±17.94 vs.77.43±10.75,Hippocampus (pg/mg·prot) TNF-α: 181.94±8.69 vs.64.83±13.09,IL-1β: 52.10±5.59 vs.17.97±2.26,P=0.000].TEM shown that the histopathological damage of hippocampus tissue in group LPS and α-BGT were heavier,which in group LPS+DEX was reversed partially.Conclusion Central alpha-2 agonist dexmedetomidine attenuates sepsis-associated delirium syndrome likely through activating cholinergic anti-inflammatory pathway and inhibiting the inflammatory responses in serum and brain.

Different cellular responses of dexmedetomidine at infected site and peripheral blood of emdotoxemic BALB/c mice.

of T cells , B cells and macrophages , activity of macrophages in the peripheral blood , and proliferation of T cells in spleen during endotoxemia

Dexmedetomidine Controls Systemic Cytokine Levels Through the Cholinergic Anti-inflammatory Pathway

Dexmedetomidine Attenuates Inflammatory Reaction in the Lung Tissues of Septic Mice by Activating Cholinergic Anti-Inflammatory Pathway

Effect of Dexmedetomidine on Humoral Immune Function in Septic Mice

Dexmedetomidine attenuates pyohemia-associated delirium in mice through the cholinergic anti-inflammatory pathway

Posttreatment with Dexmedetomidine Aggravates LPS-induced Myocardial Dysfunction Partly Via Activating Cardiac Endothelial Α2a-Ar in Mice.

Effects of dexmedetomidine on cellular immune function of immunosuppression juvenile rats

Effects of Dexmedetomidine on Immune Cells: A Narrative Review

Effect of Dexmedetomidine on JAK2/STAT3 Signaling Pathway in Mice with Endotoxin-Induced Acute Lung Injury

Dexmedetomidine Attenuates Lipopolysaccharide-Induced Inflammation Through Macrophageal IL-10 Expression Following Α7 Nachr Activation

Effect of Dexmedetomidine on Mitochondrial Dynamics in Mice with Endotoxin-Induced Acute Lung Injury

Effects of dexmedetomidine on perioperative stress, inflammation, and immune function: systematic review and meta-analysis

Effect of sedation with dexmedetomidine or propofol on gastrointestinal motility in lipopolysaccharide-induced endotoxemic mice

Dexmedetomidine alleviates non-ventilation associated lung injury via modulating immunology phenotypes of macrophages

The Role of Spleen in the Treatment of Experimental Lipopolysaccharide-Induced Sepsis with Dexmedetomidine

Dexmedetomidine alleviates cognitive impairment by reducing blood-brain barrier interruption and neuroinflammation via regulating Th1/Th2/Th17 polarization in an experimental sepsis model of mice

Dexmedetomidine post-treatment exacerbates metabolic disturbances in septic cardiomyopathy via α2A-adrenoceptor

Effect of dexmedetomidine on postoperative systemic inflammation and recovery in patients undergoing digest tract cancer surgery: A meta-analysis of randomized controlled trials

Dexmedetomidine Attenuates Lipopolysaccharide-Induced Sympathetic Activation and Sepsis via Suppressing Superoxide Signaling in Paraventricular Nucleus

Dexmedetomidine Ameliorates Muscle Wasting And Attenuates The Alteration Of Hypothalamic Neuropeptides And Inflammation In Endotoxemic Rats